Pemetrexed versus Gefitinib versus Erlotinib in previously treated patients with non-small cell lung cancer

Korean Journal of Internal Medicine

Volumn 25, Issue 3, 2010, Pages 294-300

  Hong, Junshik ^a   Kyung, Sun Young ^a   Lee, Sang Pyo ^a   Park, Jeong Woong ^a   Jung, Sung Hwan ^a   Lee, Jae Ik ^b   Park, Se Hoon ^c   Sym, Sun Jin ^a   Park, Jinny ^a   Cho, Eun Kyung ^a   Shin, Dong Bok ^a   Lee, Jae Hoon ^a  

^a Departments of Internal Medicine   (South Korea)

^b Gachon University   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Erlotinib; Gefitinib; Lung neoplasms; Pemetrexed

Indexed keywords

CYANOCOBALAMIN; DOCETAXEL; ERLOTINIB; FOLIC ACID; GEFITINIB; PEMETREXED; PLATINUM DERIVATIVE; ANTINEOPLASTIC AGENT; GLUTAMIC ACID DERIVATIVE; GUANINE; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ACNE; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER CONTROL; CANCER STAGING; CIGARETTE SMOKING; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; EDEMA; FATIGUE; FEMALE; HISTOPATHOLOGY; HUMAN; INFECTION; KARNOFSKY PERFORMANCE STATUS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PRURITUS; RECURRENT CANCER; RETROSPECTIVE STUDY; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; VITAMIN SUPPLEMENTATION; VOMITING; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; LUNG NEOPLASMS; MIDDLE AGED;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RETROSPECTIVE STUDIES;

EID: 77957043040     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2010.25.3.294     Document Type: Article

References (19)

1. Yoo KY. Cancer control activities in the Republic of Korea. Jpn J Clin Oncol 2008;38:327-333.
2. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
3. Stinchcombe TE, Socinski MA. Considerations for second-line therapy of non-small cell lung cancer. Oncologist 2008;13 Suppl 1:28-36.
4. Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000;18:122-130.
5. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
6. Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1998;16:2459-2465.
7. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with nonsmall-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103.
8. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-smallcell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597.
9. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132.
10. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-2158.
11. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced nonsmall-cell lung cancer: results from a randomised, placebocontrolled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-1537.
12. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008;372:1809-1818.
13. Boysen M, Longson C, Stevens A. Erlotinib for the treatment of non-small-cell lung cancer. Lancet Oncol 2009;10:15-16.
14. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
15. National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE) [Internet]. Bethesda (MD): National Cancer Institute - Cancer Therapy Evaluation Program, 2006 [cited at 2010 Jul 2]. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_30.
16. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909.
17. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003;21:2237-2246.
18. Korean Health Insurance Review and Assessment Service [Internet]. Korean Health Insurance Review and Assessment Service Announcement No. 2009-1. Seoul: Korean Health Insurance Review and Assessment Service, c2009 [cited 2009 Jan 01]. Available from: http://www.hira.or.kr/common/dummy.jsp?pgmid=HIRAA030103000000.
19. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.